Swain SM et al., 2003-06-01: Retrospective re-analysis of 630 patients randomised to doxorubicin plus placebo in three phase III trials. It estimated 26% cumulative CHF incidence at 550 mg/m2, higher than the older 7% estimate.
Analysis indicated that an estimated cumulative 26% of patients would experience doxorubicin-related CHF at a cumulative dose of 550 mg/m(2).
Abstract (Results)
Swain SM et al., 2003-06-01: Retrospective re-analysis of 630 patients randomised to doxorubicin plus placebo in three phase III trials. It estimated 26% cumulative CHF incidence at 550 mg/m2, higher than the older 7% estimate. Comparator: placebo-controlled arms of three phase III trials (doxorubicin + placebo), two in breast cancer and one in small-cell lung cancer; the 7% figure it overturns came from a prior retrospective study. Authors were at the National Institutes of Health (Swain) and M.D. Anderson (Ewer); funder not stated in the abstract. Second finding on the same page: more than 50% of patients who developed CHF had a LVEF reduction under 30% while on study, i.e. LVEF monitoring did not predict CHF. Study type: uncontrolled series.
